

At Page 65, line 21, after "#10," add --(SEQ ID NO:68)--.

At Page 65, line 24, after "#11," add --(SEQ ID NO:69)--.

At Page 65, line 27, after "#12," add --(SEQ ID NO:70)--.

At Page 66, line 1, after "3'," add --(SEQ ID NO:71)--.

At Page 66, line 2, after "3'," add --(SEQ ID NO:72)--.

At Page 66, line 6, after "3'," add --(SEQ ID NO:73)--.

At Page 66, line 7, after "3'," add --(SEQ ID NO:74)--.

At Page 66, line 11, after "3'," add --(SEQ ID NO:75)--.

At Page 66, line 12, after "3'," add --(SEQ ID NO:76)--.

At Page 66, line 21, after "3'," add --(SEQ ID NO:77)--.

At Page 66, line 22, after "3'," add --(SEQ ID NO:78)--.

At Page 67, line 3, after "3'," add --(SEQ ID NO:79)--.

At Page 67, line 4, after "3'," add --(SEQ ID NO:80)--.

At Page 67, line 13, after "3'," add --(SEQ ID NO:81)--.

At Page 67, line 14, after "3'," add --(SEQ ID NO:82)--.

IN THE CLAIMS:

Cancel all claims without prejudice and add the following claims:

11. A humanized antibody, comprising:

03 a human constant region and light- and heavy-chain variable regions comprising CDRs derived from a non-human antibody and framework derived from a human antibody, at least one amino acid of the human framework being substituted with

an amino acid residue from the framework of said non-human antibody, said at least one framework amino acid residue being selected from the group consisting of at least one of the amino acid residues 9, 12, 41, 42, 50, 51 and 82 of the light chain variable region and 47, 67, 70, 72, 76, 85 and 87 of the heavy chain variable region, said humanized antibody binding to the same epitope on human lymphocytes as the monoclonal antibody produced by the cell line deposited as ATCC HB 11423.

12. The humanized antibody of claim 11 wherein said at least one framework substitution comprises at least one of the amino acid residues 9, 12, 41, 42, 50, 51 and 82 of the light chain.

13. The humanized antibody of claim 11 wherein said at least one framework substitution comprises at least one of amino acid residues 47, 67, 70, 72, 76, 85 and 87 of the heavy chain.

14. The humanized antibody of ~~claim 11~~ wherein said at least one framework substitution comprises at least one of amino acid residues 9, 12, 41, 42, 50, 51, and 82 of the light chain, and at least one of amino acid residues 47, 67, 70, 72, 76, 85 and 87 of the heavy chain.

15. The humanized antibody of claim 11 wherein said at least one framework substitution comprises each of amino acid residues 9, 12, 41, 42, 50, 51 and 82 of the light chain.

16. The humanized antibody of claim 11 wherein said at least one framework substitution comprises each of amino acid residues 47, 67, 70, 72, 76, 85 and 87 of the heavy chain.

31 17. The humanized antibody of claim ~~11~~ wherein the light chain variable region comprises the polypeptide of SEQ. ID NO: 88 and the heavy chain variable region comprises the polypeptide of SEQ. ID NO: 93.

18. The humanized antibody of claim 11 wherein the light chain CDR's comprises CDRs 1, 2 and 3 of SEQ. ID NO: 88 and the heavy chain CDRs comprises CDRs 1, 2 and 3 of SEQ. ID NO: 93.

19. The humanized antibody of claim 11 wherein said at least one framework substitution comprises each of amino acid residues 9, 12, 41, 42, 50, 51 and 82 of the

light chain and each of amino acid residues 47, 67, 70, 72, 76, 85 and 87 of the heavy chain.

20. The humanized antibody of claim 11 wherein the CDRs are derived from a rat antibody.

21. A humanized antibody, comprising: a human constant region and light - and heavy-chain variable regions comprising CDRs derived from a non-human antibody and framework derived from a human antibody, said CDRs comprising the CDRs of the non-human monoclonal antibody produced by the cell line deposited as ATCC HB11423, at least one amino acid of the human framework being substituted with an amino acid residue from the framework of said non-human antibody, said at least one framework amino acid residue being selected from the group consisting of at least one of the amino acid residues 9, 12, 41, 42, 50, 51, and 82 of the light chain variable region and 47, 67, 70, 72, 76, 85, and 87 of the heavy chain variable region.

22. The humanized antibody of claim 21 wherein said at least one framework substitution comprises at least one of the amino acid residues 9, 12, 41, 42, 50, 51, and 82 of the light chain.

23. The humanized antibody of claim 21 wherein said at least one framework substitution comprises at least one of the amino acid residues 47, 67, 70, 72, 76, 85, and 87 of the heavy chain.

24. The humanized antibody of claim 21 wherein said at least one framework substitution comprises each of amino acid residues 9, 12, 41, 42, 50, 51, and 82 of the light chain.

25. The humanized antibody of claim 21 wherein said at least one framework substitution comprises each of amino acid residues 47, 67, 70, 72, 76, 85, and 87 of the heavy chain.

26. The humanized antibody of claim 21 wherein said at least one framework substitution comprises each of amino acid residues 9, 12, 41, 42, 50, 51, and 82 of the light chain and 47, 67, 70, 72, 76, 85, and 87 of the heavy chain.

DE 527. A process for treating a patient to inhibit a T-cell-mediated immune response comprising:

47 1

treating a patient by administering to a patient the antibody of claim 11 in an amount effective to inhibit a T-cell-mediated immune response.

DE 928. A process for treating a patient to inhibit a T-cell-mediated immune response comprising:

48 2

treating a patient by administering to a patient the antibody of claim 12 in an amount effective to inhibit a T-cell-mediated immune response.

DE 1029. A process for treating a patient to inhibit a T-cell-mediated immune response comprising:

49 4

treating a patient by administering to a patient the antibody of claim 13 in an amount effective to inhibit a T-cell-mediated immune response.

30. A process for treating a patient to inhibit a T-cell-mediated immune response comprising:

treating a patient by administering to a patient the antibody of claim 15 in an amount effective to inhibit a T-cell-mediated immune response.

31. A process for treating a patient to inhibit a T-cell-mediated immune response comprising:

treating a patient by administering to a patient the antibody of claim 16 in an amount effective to inhibit a T-cell-mediated immune response.

32. A process for treating a patient to inhibit a T-cell-mediated immune response comprising:

treating a patient by administering to a patient the antibody of claim 17 in an amount effective to inhibit a T-cell-mediated immune response.

33. A process for treating a patient to inhibit a T-cell-mediated immune response comprising:

treating a patient by administering to a patient the antibody of claim 18 in an amount effective to inhibit a T-cell-mediated immune response.

34. A process for treating a patient to inhibit a T-cell-mediated immune response comprising:

treating a patient by administering to a patient the antibody of claim 19 in an amount effective to inhibit a T-cell-mediated immune response.

35. A process for treating a patient to inhibit a T-cell-mediated immune response comprising:

treating a patient by administering to a patient the antibody of claim 23 in an amount effective to inhibit a T-cell-mediated immune response.

36. A process for treating a patient to inhibit a T-cell-mediated immune response comprising:

treating a patient by administering to a patient the antibody of claim 24 in an amount effective to inhibit a T-cell-mediated immune response.

37. A process for treating a patient to inhibit a T-cell-mediated immune response comprising:

treating a patient by administering to a patient the antibody of claim 25 in an amount effective to inhibit a T-cell-mediated immune response.

38. The process of claim 28 wherein the patient is treated for graft rejection.

39. The process of claim 29 wherein the patient is treated for graft rejection.

40. The process of claim 33 wherein the patient is treated for graft rejection.

41. The process of claim 28 wherein the patient is treated to prevent graft rejection.

42. The process of claim 29 wherein the patient is treated to prevent graft rejection.

43. The process of claim 33 wherein the patient is treated to prevent graft rejection.

44. The process of claim 28 wherein the patient is treated for graft-versus-host disease.

45. The process of claim 29 wherein the patient is treated for graft-versus-host disease.

46. The process of claim 33 wherein the patient is treated for graft-versus-host disease.

Reconsideration and reexamination of this application are requested.

REMARKS

The specification has been amended.

143